Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2.

ABSTRACT:

Background

Patients with cancer have high risk for severe complications and poor outcome to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease [coronavirus disease 2019 (COVID-19)]. Almost all subjects with COVID-19 develop anti-SARS-CoV-2 immunoglobulin G (IgG) within 3 weeks after infection. No data are available on the seroconversion rates of cancer patients and COVID-19.

Patients and methods

We conducted a multicenter, observational, prospective study that enrolled (i) patients and oncology health professionals with SARS-CoV-2 infection confirmed by real-time RT-PCR assays on nasal/pharyngeal swab specimens; (ii) patients and oncology health professionals with clinical or radiological suspicious of infection by SARS-CoV-2; and (iii) patients wit

SUBMITTER: Marra A 

PROVIDER: S-EPMC7577226 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature